AB2 Bio triggers $30M milestone as Nippon Shinyaku takes up US option

Source Summary

Nippon Shinyaku Co. Ltd. has taken up its option on U.S. rights to AB2 Bio Ltd.’s interleukin-18 neutralizing drug, tadekinig alfa, triggering a payment of $30 million and opening the way to a further $650 million in development and commercialization milestones for the Swiss biotech. The rights relate to the use of tadekinig in the treatment of primary pediatric IL-18-driven hyperinflammation, an ultra-rare inherited disorder that if left untreated can lead to multi-organ failure and death.